Solid Cancer clinical trials

Explore recruiting solid cancer clinical trials.

Recruiting solid cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Solid Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor

Belgium, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Pan-lesions SBRT combined with lymphocyte support through ATRA-driven blockade of MDSC in patients with oligometastatic solid cancer (LySATRA)

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

LAG3 PET; ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemiplimab with or without platinum-based chemotherapy

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors

Spain, Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Solid Cancer trials by city

Solid Cancer in Toronto Solid Cancer in Vancouver Solid Cancer in Montreal Solid Cancer in Calgary Solid Cancer in Edmonton Solid Cancer in Ottawa Solid Cancer in Winnipeg Solid Cancer in Quebec City Solid Cancer in Hamilton Solid Cancer in Kitchener Solid Cancer in London Solid Cancer in Halifax Solid Cancer in New York Solid Cancer in Los Angeles Solid Cancer in Chicago Solid Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease